Antibody response and cross-neutralization after Omicron BA.2 infection
作者机构：Institute of Human VirologyKey Laboratory of Tropical Disease Control of Ministry of EducationGuangdong Engineering Research Center for Antimicrobial Agent and ImmunotechnologyZhongshan School of MedicineSun Yat-sen UniversityGuangzhouGuangdong510080China Shenzhen Center for Disease Control and PreventionShenzhen518055GuangdongChina Shenzhen Third People’s HospitalSecond Hospital Affiliated to Southern University of Science and TechnologySouth China Hospital of Shenzhen UniversityShenzhen518011GuangdongChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2023年第8卷第2期
页 面：348-350页
核心收录：
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
基 金：This work was supported by the National Key Research and Development Program of China 2022YFC0870700 the Natural Science Foundation of China 92169201 and 82150710553,and Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou to H.Z This work was supported by the Natural Science Foundation of China,92169108 and 32000613 to Y.Z the Shenzhen Science and Technology Innovation Commission Key project JSGG20200225152648408 Special project for 2019-nCoV epidemic emergency prevention of the Shenzhen Science and Technology Innovation Commission JSGG20220606141401003 to Y.H
主 题：Antibody acute respiratory
摘 要：Dear Editor,The Omicron(B.1.1.529)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was first identified in November 2021,in South Africa and *** first Omicron sub-lineage that emerged was BA.1,which was supplanted by BA.2 in many *** of the most notable features of the Omicron variant is its ability to evade neutralizing antibodies(nAbs)targeting the original virus lineages.
维普期刊数据库